DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1956)

Dry and Wet Age-Related Macular Degeneration | Special Topics | Special Topics: Biosimilar Anti-VEGF Agents (US)

Dry and Wet Age-Related Macular Degeneration | Special Topics | Special Topics: Biosimilar Anti-VEGF Agents (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Coming Soon – June 2019

The development of biosimilar versions of Lucentis and Eylea is of high interest in the ophthalmology market given the high cost of these agents, the large patient population suffering from neovascular retinal diseases, and the need for frequent administration of these VEGF inhibitors to maintain/improve visual acuity. Biosimilars of ranibizumab are in late-phase development and are expected to launch within the next one to two years in the major drug markets; Eylea’s patents are not expected to expire until 2021 at the earliest, so biosimilar development of aflibercept slightly lags. Avastin may not face the same threat from biosimilars in ophthalmologic indications because it is typically compounded and is already low-cost. Regardless, marketers of anti-VEGF agents will need to understand the potential patient share impact of biosimilars to diversify and respond to revenue losses.


  • What factors most influence ophthalmologists’ choice among current anti-VEGF brands? Do ophthalmologists have any concerns about the clinical characteristics of biosimilar anti-VEGF therapies compared with branded products?
  • How will ophthalmologists adopt biosimilar anti-VEGF therapies into their practice? What portion of patients do ophthalmologists expect will be prescribed biosimilar anti-VEGF therapies instead of branded products?
  • What portion of patients who are maintained on existing brands do ophthalmologists think will be switched to biosimilar products? How will the availability of biosimilar anti-VEGF therapies affect the uptake of emerging products, such as Novartis’s brolucizumab and Allergan’s abicipar pegol?
  • Do ophthalmologists expect anti-VEGF biosimilar treatment patterns to vary by indication? How do they expect reimbursement factors to affect their use of biosimilar anti-VEGF agents?


Geographies: United States

Primary research: Survey of 100 U.S. ophthalmologists

Key drugs covered: Avastin, Eylea, Lucentis, and emerging biosimilar anti-VEGF therapies

Key insights provided: Physician-reported anti-VEGF treatment practices, factors influencing choice of branded anti-VEGF agents, expected use patterns for emerging biosimilars of anti-VEGF agents in neovascular retinal diseases, expected impact of biosimilar anti-VEGF agents on the use of current and emerging therapies


Primary market research survey available for download.

Table of contents

  • Special Topics: Biosimilar Anti-VEGF Agents (US)
    • Coming Soon
      • Coming Soon

Already a Client? Log in to access this report.

  • Pub Date: February 2019
  • Author(s): Natalie Taylor, PhD
  • Natalie Taylor, is a Principal Business Insights Analyst with the central nervous system/ophthalmology disorders team at Decision Resources Group. She has over ten years of experience authoring primary and market research reports for pharmaceutical industry clients across multiple psychiatry, pain, neurology, and ophthalmology therapy areas. Prior to joining DRG, Dr. Taylor worked at QuintilesIMS as manager of the central nervous system portfolio of Disease Insights market forecasting offerings. She completed her in Physiology at Dartmouth College in Hanover, New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a in Biology from Dickinson College in Carlisle, Pennsylvania.

Purchase Report

Recent reports:
You may also be interested in: